CU6 Stock Overview
A clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.72 |
| 52 Week High | AU$7.25 |
| 52 Week Low | AU$0.97 |
| Beta | 1.56 |
| 11 Month Change | 4.02% |
| 3 Month Change | 54.48% |
| 1 Year Change | 510.91% |
| 33 Year Change | 355.59% |
| 5 Year Change | n/a |
| Change since IPO | 348.00% |
Recent News & Updates
Recent updates
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Jan 03
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow
May 29Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth
Aug 24Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation
Jan 13Shareholder Returns
| CU6 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 11.4% | 1.5% | 2.2% |
| 1Y | 510.9% | 53.5% | 11.1% |
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned 53.5% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 11.1% over the past year.
Price Volatility
| CU6 volatility | |
|---|---|
| CU6 Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CU6's share price has been volatile over the past 3 months.
Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 41 | Colin Biggin | www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CU6 fundamental statistics | |
|---|---|
| Market cap | AU$2.12b |
| Earnings (TTM) | -AU$42.32m |
| Revenue (TTM) | AU$14.28m |
148.4x
P/S Ratio-50.1x
P/E RatioIs CU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU6 income statement (TTM) | |
|---|---|
| Revenue | AU$14.28m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$14.28m |
| Other Expenses | AU$56.60m |
| Earnings | -AU$42.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -296.43% |
| Debt/Equity Ratio | 0% |
How did CU6 perform over the long term?
See historical performance and comparison